Regulatory Update – June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee (PCAC)

 

Regulatory Update – June 8, 2022 Meeting of the Pharmacy Compounding Advisory Committee (PCAC)

What is the Pharmacy Compounding Advisory Committee?

The Pharmacy Compounding Advisory Committee (PCAC) provides advice to the Food and Drug Administration (FDA) regarding scientific, technical, and medical issues that pertain to sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act).

 

What is the significance of the upcoming PCAC meeting?1

Currently, pharmacies operating under section 503A of the FD&C Act may only compound with a bulk drug substance if it meets one of the following three requirements[JHMI1] :

1. Comply with an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph if one exists, and the USP chapter on pharmacy compounding;

2. Are components of FDA-approved drug products if an applicable USP or NF monograph does not exist; or

3. Appear on FDA’s list of bulk drug substances that can be used in compounding (the 503A bulks list) if such a monograph does not exist and the substance is not a component of an FDA-approved drug product.

PCAC hosts meetings periodically during which bulk drug substances are evaluated for potential inclusion on the FDA’s 503A Bulk Substances List (i.e., the “positive list”). The upcoming PCAC meeting, scheduled to occur on June 8, 2022, will evaluate glutathione, ferric subsulfate, enclomiphene citrate, and ammonium tetrathiomolybdate.2 Currently, the FDA is proposing that all four of these bulk drug substances NOT be included on the positive list.3

 

How is Fagron working to support the interests of compounding pharmacists?

Fagron and Letco have filed a detailed comment to PCAC in support of continued use of glutathione in compounding.  We are also working with other organizations to assist in the development of a unified approach, including both written comments and oral presentations, to PCAC.

 

What can be done to make your opinion known?

Comments may be submitted to the docket at this link: https://www.regulations.gov/document/FDA-2021-N-0357-2586.  Comments must be submitted on or before June 7, 2022. The meeting broadcast details may be found at 2022 Meeting Materials, Pharmacy Compounding Advisory Committee | FDA.

 

 

Sources:

1.        Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. US Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act | FDA. Updated 2/20/2020. Accessed 5/20/22

2.       https://www.fda.gov/advisory-committees/advisory-committee-calendar/june-8-2022-meeting-pharmacy-compounding-advisory-committee-meeting-announcement-06082022

3.      https://www.fda.gov/media/158541/download

4.      https://www.regulations.gov/document/FDA-2021-N-0357-2586


Comments

Post a Comment

Popular posts from this blog

Guidance for Industry 256: Understanding Impacts on the Compounding Industry

  Guidance for Industry 256: Understanding Impacts on the Compounding Industry By Sarah Taylor, PharmD What is Guidance for Industry (GFI) 256? GFI 256 is a guidance for industry intended to provide clarification from the FDA on compounding animal drugs from bulk drug substances. The guidance does not apply to animal drugs compounded from FDA-approved animal or human drugs, which the FDA generally considers to be legal extra label uses of such drugs. 1 The FDA considers compounding animal drugs from bulk substances by pharmacists and veterinarians to violate aspects of the FD&C Act. Given the wide range of animal species and their varying needs, the FDA acknowledges that in some circumstances there may be no medically appropriate commercially available treatment options or commercially available FDA approved drugs may not be suitable for use as a source of active pharmaceutical ingredient (API) in some circumstances. This guidance lays out the circumstances in which the FDA
Read more

Developing Standard Operating Procedures

Image
 Developing Standard Operating Procedures by Denise M. Frank, RPh, FACA, FAPC   Policies and Procedures are the written pharmacy documents that include the policy statement (a course or plan of action, a high-level principle of the pharmacy), and the procedures for complying or carrying out a task. These procedures are also referred to as Standard Operating Procedures, or SOPs. Why do we need Policies and Procedures, and Standard Operating Procedures (SOPs) for the pharmacy? Policies and procedures will provide for the consistent performance of activities. Personnel have a reference on how to handle situations and perform tasks – working as a team. The manual will very useful when training new employees with clear explanations, instructions, and expectations for specific tasks and for their position. Well-written SOPs also help protect a pharmacy from liability. The policies and procedures, when followed, ensure staff are compliant with regulations and standards and this protects
Read more

Water Activity: USP 795 Changes

  Water Activity: USP <795> Changes Sarah Taylor, PharmD Beyond-use dating in the newly proposed USP General Chapter <795> underwent significant changes, particularly to the recommended maximum beyond-use dates allowed for different types of formulations. One of the biggest changes is a new focus on microbial growth and preservative efficacy. The guidelines define aqueous preparations as those having a water activity (a w ) greater than or equal to 0.6, and only preparations with an a w less than 0.6 are considered anhydrous dosage forms. 1   What is water activity? Water activity is a measurement of the ratio of vapor pressure of the substance in question when at equilibrium with the surrounding air to the vapor pressure of distilled water under identical conditions. 2 So, for example, an a w of 0.6 means that the vapor pressure of the substance in question is 60% that of pure water. Water activity should not be mistaken for water content. Water content is a meas
Read more